The case for & against
Bull & Bear analysis
Bullish
Passage Bio, Inc. (NASDAQ: PASG) operates as a clinical-stage genetic medicines company that focuses on developing innovative gene therapies for rare central nervous system (CNS) disorders with significant unmet medical needs, including conditions such as GM1 gangliosidosis and frontotemporal dementia (FTD). Positioned at the forefront of gene therapy development, the company leverages proprietary adeno-associated virus (AAV) technology to create transformative therapies aimed specifically at rare and pediatric disorders.
Bull says
- ↑Q4’22 cash $189.6M funds operations into H1 2025
- ↑Q4’22 net loss narrowed to $27.1M vs $51.2M YoY
- ↑IMAGINE-1 GM1 trial: eight patients dosed; safety/biomarker data by mid-2023
- ↑High institutional interest: elevated 13F ownership and strong quality metrics
- ↑Book-to-Price ratio ~1.25 suggests relative undervaluation
- ↑R&D spend down 47% YoY to $17.7M, improving cash efficiency
Bear says
- ↓Annual net loss $136.1M underscores heavy cash burn
- ↓Profitability and growth metrics are deeply negative
- ↓Cash reserves fell from $315.8M to $189.6M in one year
- ↓FDA-mandated 60-day interval between patients delays trials
- ↓CRAB-A program discontinuation raises strategic uncertainty
- ↓Small size relative to peers heightens competitive vulnerability
Earnings Call · Q4 2021 · Mgmt. Guidance
Updated 08-02-2026bullish
Transcript signals
Bull points
- As a result, we now have a robust and differentiated CNS pipeline that spans pediatric and adult as well as rare and large disorders.
- With these early results, we are experiencing strong interest and momentum in our GM1 program. So much so, we recently reported that we have already achieved one of our key 2022 goals, which is the dosing of the first patients in cohorts two and three for the IMAGINE ONE trial.
- We expect to report interim safety and biomarker data for each cohort in the second half of 2022.
Bear points
- Net loss was $51.2 million and $185.4 million for the quarter and year ended December 31st, 2021, compared to $38.9 million and $112.2 million for the quarter and year-ended in 2020
Read full transcript analysis ›